Evidence map›Paper›PMID 32160365›Full record

Trial reportCancer science2020

Long-term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer.

Ken Kato, Yuichiro Doki, Takashi Ura, Yasuo Hamamoto, Takashi Kojima, Takahiro Tsushima, Shuichi Hironaka, Hiroki Hara, Toshihiro Kudo, Satoru Iwasa and 6 more

Open access · goldAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 3 pooled it
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 10 institutions in 1 country.

Ken KatoDepartment of Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan.ORCID https://orcid.org/0000-0002-1733-5072
Yuichiro DokiDepartment of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.
Takashi UraDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Yasuo HamamotoKeio Cancer Center, Keio University School of Medicine, Tokyo, Japan.
Takashi KojimaDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.ORCID https://orcid.org/0000-0002-2554-8334
Takahiro TsushimaDivision of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Shuichi HironakaClinical Trial Promotion Department, Chiba Cancer Center, Chiba, Japan.ORCID https://orcid.org/0000-0001-9714-231X
Hiroki HaraDepartment of Gastroenterology, Saitama Cancer Center, Saitama, Japan.
Toshihiro KudoDepartment of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Osaka, Japan.
Satoru IwasaDepartment of Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan.
Kei MuroDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Hirofumi YasuiDivision of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Keiko MinashiClinical Trial Promotion Department, Chiba Cancer Center, Chiba, Japan.
Kensei YamaguchiDepartment of Gastroenterology, Saitama Cancer Center, Saitama, Japan.
Atsushi OhtsuNational Cancer Center Hospital East, Kashiwa, Japan.
Yuko KitagawaDepartment of Surgery, Keio University School of Medicine, Tokyo, Japan.
National Cancer Center Hospital East · JPKeio University · JPSaitama Cancer Center · JPShizuoka Cancer Center · JPAichi Cancer Center · JPChiba Cancer Center · JPKyoto Medical Center · JPOita University · JPOsaka International Cancer Institute · JPThe University of Osaka · JP

Funding

Bristol-Myers SquibbOno Pharmaceuticals
6 · The paper itself

Abstract

The long-term efficacy of nivolumab in esophageal squamous cell carcinoma and its association with disease biomarkers are currently not well known. Therefore, we investigated the association in Japanese patients with treatment-refractory advanced esophageal cancer who participated in an open-label, single-arm, multicenter phase II study. Patients received nivolumab 3 mg/kg i.v. every 2 weeks until disease progression or unacceptable toxicity, and were followed up for 2 years after the initial dosing of the last patient. Archival tissue samples were collected before treatment and analyzed for programmed death ligand-1 (PD-L1) and CD8

Indexed as

AgedAged, 80 and overAntineoplastic Agents, ImmunologicalB7-H1 AntigenBiomarkers, TumorCD8 AntigensDrug Resistance, NeoplasmEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaFemaleFollow-Up StudiesHistocompatibility Antigens Class IHumansJapanLymphocytes, Tumor-InfiltratingMaleAntineoplastic Agents, ImmunologicalB7-H1 AntigenBiomarkers, TumorCD274 protein, humanCD8 AntigensHistocompatibility Antigens Class INivolumabCD8+ tumor-infiltrating lymphocyteesophageal squamous cell carcinomalong-term survivalnivolumabprogrammed death-1

Identifiers

PMID32160365
PMCPMC7226206
OpenAlexW3012256786

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.